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The first annual workshop for preclinical and clinical development of radiosensitizers took place at the National Cancer Institute 
on August 8–9, 2012. Radiotherapy is one of the most commonly applied and effective oncologic treatments for solid tumors. It 
is well recognized that improved clinical efficacy of radiotherapy would make a substantive impact in clinical practice and patient 
outcomes. Advances in genomic technologies and high-throughput drug discovery platforms have brought a revolution in cancer 
treatment by providing molecularly targeted agents for various cancers. Development of predictive biomarkers directed toward 
specific subsets of cancers has ushered in a new era of personalized therapeutics. The field of radiation oncology stands to gain 
substantial benefit from these advances given the concerted effort to integrate this progress into radiation therapy. This work-
shop brought together expert clinicians and scientists working in various disease sites to identify the exciting opportunities and 
expected challenges in the development of molecularly targeted agents in combination with radiation therapy.
J Natl Cancer Inst;2013;105:686–693 
The overarching goal of radiation therapy is to achieve the most 
optimal therapeutic index. Most innovations in the past half-cen-
tury have been focused on ways of delivering treatment so that 
normal organ toxicity can be minimized while a therapeutic dose 
can be delivered. Advances in computational technologies and 
imaging innovations have led to marked improvements in radia-
tion planning and therapeutic delivery. The incorporation of the 
computed tomography scan for treatment planning has brought 
treatment delivery from two-dimensional to three-dimensional 
planning. Consequently, the advances in both treatment plan-
ning and delivery have reduced toxicity, allowed escalation of 
dose to the tumor, and consequently improved clinical outcomes 
(1–4). Although there continue to be new advances in how treat-
ment is planned and delivered, advances in the field of radiation 
oncology have gradually met a plateau where the therapeutic 
index cannot be further improved because of physical limita-
tions and dose-limiting structures. For additional progress to 
be made, technological innovations must be complemented by 
biological innovations, such as development of novel radiosensi-
tizing agents and biology-driven patient selection. In this com-
mentary, we summarize the collective scientific output from the 
first annual workshop for preclinical and clinical development 
of radiosensitizers at the National Cancer Institute on August 
8–9, 2012, and provide recommendations for the rational and 
accelerated development of radiation-based combination ther-
apy (see Table 1).
Challenges and opportunities in 
Developing molecularly targeted  
therapies in Combination With radiation
The choice of agents to combine with radiation is an important 
consideration. New agents that are developed in combination 
with radiotherapy should have: 1) a single-agent activity, and/or 2) 
a radiation-enhancing effect, either as a direct radiation sensitizer 
or as a synthetically lethal combination when administered with 
radiation. The definition of radiation enhancement is complex 
because it may involve both a direct radiation-sensitizing effect and 
indirect effects (5). We recognize that there are specific challenges 
in developing radiosensitizing agents. Before embarking on large-
scale clinical trials, adequate preclinical data should be acquired to 
support such hypotheses.
Preclinical Testing and Model Systems
Mechanisms of action must be explored using preclinical experi-
ments. When embarking on preclinical studies evaluating the 
combination of molecular targeted therapies and radiation, the first 
step is to determine the appropriate system (cell culture or animal 
models) in which to evaluate the combination. In vitro clonogenic 
survival assays or apoptotic assays may be needed to demonstrate 
preclinical activity of agents that may have direct cytotoxic effects on 
the cells themselves (eg, tyrosine kinase inhibitors blocking tumor 
EGFR mutations) to illustrate the additive effect of the agent over 
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radiation alone. Agents that act upon the tumor microenvironment 
to influence tumor growth (eg, antiangiogenic agents, anti-HGF 
antibodies) may require in vivo assays to establish their activity in 
combination with radiation.
A spectrum of in vitro and in vivo models may be used for 
testing the preclinical efficacy of combining radiation therapy 
with molecularly targeted agents. In vitro models could include 
the use of cell lines in tissue culture or in three-dimensional cul-
tures. In vivo model systems include cell line-derived xenografts 
(6), patient tumor-derived xenografts, and genetically engineered 
mouse models that form tumors spontaneously by conditionally 
expressing a gene of interest (7). However, no matter how intri-
cate these systems are, none fully reflects the degree of diversity 
and complexity seen in human cancers. For certain disease sites 
(eg, salivary gland tumors) or agents (eg, immunomodulators such 
as anti–CTLA-4 antibodies), there are simply no appropriate pre-
clinical models.
Although inadequate to address all the nuances and complexi-
ties of human physiology and cancer biology, preclinical studies 
remain a valuable tool to confirm mechanisms of action and radi-
oenhancement properties when conducted appropriately. We feel 
that at a minimum, there should be in vitro data from at least two 
cell lines derived from the disease of interest (eg, lung cancer cell 
lines for a lung cancer proposal) when they are available, and data 
should not be extrapolated from unrelated cell lines. Because it is 
important to study host-tumor effects and to confirm findings in 
a more complex system, in vivo animal studies are generally rec-
ommended; therefore, whenever established animal model systems 
are available, they should be used to support clinical trial propos-
als. However, because no model system perfectly recapitulates the 
human condition and each system has its own inherent limitations, 
there is no panel consensus on specific recommendations about the 
best use of the in vivo system. At a minimum, subcutaneous flank or 
intramuscular thigh models may be sufficient to test in vivo efficacy 
Table 1. Summary of workshop recommendations for the accelerated development of novel targeted radiation enhancers 
Determination of agent activity
1.1 Agents of interest should enhance radiation effects through either synergistic or additive mechanisms but, if not, should at least have 
single-agent or combination activity with chemotherapy.
1.2 Preclinical testing is crucial to provide evidence that the agent of interest has radiation enhancement effect; At least two cell lines 
from the same disease site should be required, whereas in vivo animal testing should be used to further demonstrate radiation 
enhancement effect whenever a suitable animal model for the cancer type exists.
1.3 When generation of in vitro or in vivo preclinical data is not feasible, strong justification must be provided for the inability to perform 
these studies before proposing a clinical study.
Prioritizing agent development
2.1 The development of radiation-enhancing agents should be prioritized when biomarker-based patient selection is available.
2.2 Agents without validated predictive biomarkers available for clinical testing could be brought into clinical testing but with the mandate 
that there are clear plans for concurrent preclinical research and clinical development of predictive biomarkers from pretreatment 
tissue specimens.
2.3 Concurrent development of predictive biomarkers should be a priority during the preclinical and early clinical phases of testing followed 
by subsequent clinical validation. Clinical studies must mandate pretreatment tumor biopsy and/or serum collection, with strong 
 consideration given to acquisition of serial tissue collection during early therapy and at the time of recurrence.
2.4 Understanding the proper sequencing of combining targeted agents with radiation therapy will be important before carrying out large 
clinical trials.
Safety
3.1 Phase I studies are critical to determine the safety of combining a new agent with radiation (or chemoradiation), but this should only be 
a site-specific and not a disease-specific requirement. For instance, clinical testing of a novel agent with radiation for rectal cancer 
need not be repeated for prostate cancer, cervical cancer, or other pelvic tumors.
3.2 A minimal 30-day observational period after completion of radiotherapy should be used to gauge the acute toxicities of a novel 
treatment.
3.3 Late toxicity should be monitored in early-phase clinical trials even when acute toxicity is used as a primary safety endpoint.
Clinical trial designs
4.1 Alternative innovative phase I designs (eg, time-to-event continuous reassessment method) should be considered to improve study 
efficiency and cumulative safety analysis.
4.2 An efficient way to rapidly test novel agents in combination with radiation is through a modular clinical trial platform, in which several 
agents/combinations are individually tested in parallel noncomparative arms.
4.3 The economic benefits and a platform-based clinical trial design should be recognized and prioritized.
Regulatory
5.1 Both the US Food and Drug Administration (FDA) and the pharmaceutical industry should acknowledge that combination trials with 
radiation can help to dramatically improve cure rates of nonmetastatic patients, representing a new pathway for expediting the drug 
approval process. The FDA should issue an advisory clarifying requirements for approval of an agent in combination with radiotherapy 
or with a previously established chemotherapy and radiation therapy combination.
5.2 The Cancer Therapy Evaluation Program (CTEP) should consistently issue mass solicitations for drug combination trials that have specific 
calls for proposals in combination with radiation and simultaneously facilitate development of compounds as radiosensitizers within 
the CTEP portfolio.
5.3 The development of novel radiation sensitizers should be financially supported consistent with other priorities in cancer research.
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to verify cell culture results. When there is not a standard or estab-
lished model system that can be applied to the specific cancer type, 
in vivo preclinical validation may not be required for a clinical trial 
proposal. In these situations, data from other disease sites with the 
same agent/radiation combinations could justify exploratory stud-
ies in the disease site of interest.
Selection of Candidate Agents of Interest
Given the number of candidate agents in the pipeline or in early 
clinical testing, it will be nearly impossible to test every combi-
nation with radiation. Many novel agents have mechanisms of 
action that are scientifically poised to serve as radiation enhanc-
ers. However, a comprehensive listing of the data to support this 
statement is beyond the scope of this article. Although these agents 
target various molecular pathways in a diversity of disease sites, we 
believe many of the potentially radiation-sensitizing drugs of inter-
est can be broadly placed into two groups based on the maturity 
of translational and clinical data: agents with established biomark-
ers of response or agents with biomarkers in development. Specific 
examples of these two groups of agents are listed in Table 2.
Agents With Established Biomarkers of Clinical Benefit
Agents in this group have some clinical or preclinical evidence to 
support specific biomarkers that are predictive for clinical benefit. 
These biomarkers are mostly tumor-specific biomarkers, which, 
when present, can be used to select optimal patients for specific 
treatment. These agents are mostly inhibitors targeting activated 
tyrosine kinases, serine/threonine kinases, cell cycle regulators, 
and/or hormonal receptors. For most of these compounds, there 
is compelling clinical evidence that the response to therapy is pre-
dicted by the presence of specific biomarkers reflecting a clear 
on-target effect [EGFR mutations (8), ALK or ROS1 transloca-
tion (9,10), Her-2 overexpression (11), estrogen receptor expres-
sion (12)], whereas some other agents in early development lack 
such clinical association, having only preclinical data [chk1/wee1-
TP53 mutation(13)]. Many of these agents demonstrate consid-
erable activity in appropriately selected patient populations but 
appear relatively ineffective when used in an unselected manner 
(Figure 1A). To accelerate development, we recommend the pri-
oritization of radiosensitizer development in compounds or classes 
for which biomarker-based patient selection is currently available.
Agents With Biomarkers in Development
There are many other agents that currently do not have validated 
biomarkers (Table 2), despite having a specific target known to be 
important for cancer development, growth, invasiveness, or meta-
static spread. Although there may be gene signatures (eg, mRNA 
expression, methylation, microRNA) that may be associated with 
response from retrospective analysis of clinical samples, these sig-
natures should not be used for patient selection until the comple-
tion of prospective validation studies. The disease-free survival 
results from these studies often differ substantially from agents 
with established biomarkers (Figure 1B). Of note, the radiosensiti-
zation properties of any given class of agents might still be effective 
in a nonselected patient population if the mechanism of radia-
tion enhancement is not known, but the degree of radiosensitiza-
tion is profound in preclinical studies. In this case, testing a novel 
agent with radiation therapy in the absence of a biomarker may be 
Table 2. Select examples of novel agents based on the currently available biomarkers for patient selection 
Agents with established biomarkers
Drug Targets Biomarker
Erlotinib EGFR EGFR mutations
Crizotinib ALK/ROS1 fusion genes EML4/ALK and ROS1 fusion
Vemurafenib, dabrafenib BRAF BRAF mutations
MK-1775 Wee-1 TP53 mutations
MK-8776 Chk-1 TP53 mutations
Nutlin-3 MDM2 TP53 WT
ARQ-197, XL-184 c-MET c-MET mutations
Trametinib, salumetinib MEK1/2 K-ras mutations
BEZ235 PI3K/mTOR/DNA-PK K-ras/PIK3CA/PTEN mutations
AZD1480 JAK2 TEL-JAK2 fusion
Trastuzumab Her-2 Her-2 overexpression
Tamoxifen, aromatase inhibitors ER ER expression
Agents with promising biomarkers in development
Drug Targets Potential Biomarker
Bevacizumab, aflibercept VEGF VEGF-A
Vorinostat HDAC —
Azacytidine DNA, DNMTs —
ABT-888 PARP 1 or 2 —
Cisplatin DNA ERCC1
5-FU Thymidylate synthase —
Gemcitabine Ribonucleotide reductase hENT1
Bortezomib 26S proteasome —
RO4929097 Notch —
BMS 833923 Smoothened —
Fostamatinib SYK —
Cetuximab EGFR Kras mutation is a negative prognostic factor
Ipilimumab CTLA-4 CTLA-4 expression
BMS-936558 PD-1 PD-1 expression
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appropriate. Thus this developmental prioritization requires ongo-
ing refinement. Although we recognize that there may be some 
caveats with the broad grouping of these compounds, we believe 
it encompasses the majority of agents to be brought forward into 
clinical testing with radiotherapy.
Strategies to Develop Predictive Biomarkers for Agents 
of Interest
To bring agents with established biomarkers into clinical test-
ing with radiation, there must be some preclinical evidence that 
demonstrates evidence for synergy with radiotherapy as previously 
stated. Early phases of testing should focus on confirming activity 
and identifying mechanisms of resistance. To improve the likeli-
hood of clinical success, concurrent development of potentially 
predictive biomarkers should be a priority during the preclinical 
and early clinical phases of testing followed by subsequent clini-
cal validation. Clinical studies must mandate pretreatment tumor 
biopsy with strong consideration given to acquisition of additional 
tissue early during therapy and again at the time of recurrence with 
appropriate safety and incentives for such a priority. Paired samples 
of pretreatment and early on-treatment biopsies might provide not 
only biomarkers of treatment resistance detected upfront but also 
dynamically changing biomarker profiles suggestive of inducible 
molecular resistance pathways that might overcome treatment 
efficacy.
Determining the Sequence of Combining Radiation
It is often assumed that sensitizers must be added concurrently with 
radiation for synergistic effect. However, this may not always be the 
case. Depending on the mechanism of action of the targeted drugs, 
concurrent administration may even have antagonistic effects. For 
instance, because radiation cytotoxic effects are highly dependent 
on the cell-cycle phase, with the greatest sensitivity occurring at 
the G2/M phase, and the greatest resistance in the G1/S phase (14), 
drugs that cause cell-cycle arrest or prolong cells in the radiore-
sistant phase of the cell cycle may jeopardize the radiation effect. 
Therefore the appropriate timing and sequencing of the combi-
nation must be considered as well. Although Bonner et  al. dem-
onstrated survival benefit in head and neck cancers treated with 
cetuximab and radiation compared with radiation alone (15), add-
ing cetuximab to chemoradiation did not improve survival rates 
over chemoradiation alone, as shown in RTOG 0522 (16). Several 
theories have been advanced to explain why addition of cetuxi-
mab to chemoradiation did not show survival benefit, including 
an overlapping mechanism of action between cetuximab and cispl-
atin as radiation sensitizers. However, the EXTREME trial, which 
used cetuximab maintenance until disease progression, suggests 
cetuximab may be best used as a maintenance monotherapy after 
completing the primary treatment. Additionally, this may be a dis-
ease-specific phenomena because the phase II trial in lung cancer 
using cetuximab and a different combination chemotherapy regi-
men (carboplatin/paclitaxel) was promising (17) and is currently 
being tested in RTOG 0617. Therefore, mechanisms of interac-
tion between targeted agents, radiation, and/or chemoradiotherapy 
should be carefully evaluated in preclinical models and in early-
phase clinical trials before definitive studies are undertaken.
Phase I Clinical Safety
As is true for all preclinical models, demonstration of radiation 
enhancement in the laboratory may not translate to activity in the 
clinical setting. Thus clinical testing in patients is required to dem-
onstrate both safety and subsequent efficacy. Many of the agents 
being considered as radiosensitizers are also being tested alone or 
in combination with standard chemotherapy. Most of these clini-
cal trials are conducted in the advanced disease setting after mul-
tiple lines of standard therapeutics. The safety data from these 
studies, although important to identify unique ancillary testing 
requirements (eg, electrocardiogram, echocardiography, ophthal-
mic exams, specific blood tests), are not sufficient to confirm the 
dose and safety when used in combination with radiation. Thus, 
for every concept incorporating a new agent with radiotherapy, a 
phase I study to demonstrate dose and safety must be performed. 
Figure  1. Hypothetical examples of Kaplan–Meier overall survival 
curves comparing drug developments in a selected patient popula-
tion based on biomarkers vs unselected patient population. A) Like 
many drug trials directed at specific populations of patients based on 
biomarker selection, the initial part of the curve separates early in the 
targeted agent group (Drug X) compared with the standard of care 
(SOC) arm, but eventually resistance develops in the majority of these 
patients. B) For a trial testing the efficacy of Drug X in an unselected 
group of patients, practically no real separation is seen in the curves 
between the experimental (Drug X + SOC) and SOC arms early on; the 
curves eventually split, and a statistically significant separation occurs 
later in the trial, with some patients having durable responses.
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This could be met by a standard single-arm phase I  study or a 
safety run-in component in a phase I/II trial. Combination therapy 
at completely different anatomic sites cannot be used to general-
ize the safety of the combination. However, data obtained where 
a drug is evaluated in combination with radiotherapy in the same 
anatomic region (eg, esophageal cancer and lung cancer) could be 
used. In summary, safety data of phase I trials combining radiation 
and novel agents should be more organ/location specific rather 
than cancer specific.
The observational period to determine the toxicity of radiation 
combination trials must balance the time it takes for acute/subacute 
effects to take place and the practicality of carrying out studies in a 
timely fashion under time, patient, and logistical constraints. This 
timing may also differ between the organ at risk and individual sus-
ceptibility. Currently, a 3 + 3 design (n = 3 patients to enroll at each 
dose level, with toxicity to keep below 33%, or n = 1 patient or 
less to establish maximum tolerated dose [MTD]) is the traditional 
approach for phase I clinical trial designs. Unfortunately, with the 
requirement of complete toxicity monitoring of all three patients 
at each dose level for the time window, this process is inefficient 
and often stalls trial advancement. The use of alternative statisti-
cal designs, such as time-to-event continuous reassessment method 
could improve the enrollment efficiency and cumulative safety 
analysis of phase I trials (18). As is true for nonradiotherapy safety 
reporting, a minimum 30-day observational period after comple-
tion of treatment should be used to monitor for toxicities. This 
period will account for the majority of acute toxicities of therapies 
(which typically develop within 2 to 3 weeks of the start of radia-
tion) and follows the patient until toxicity recovery (typically 2–3 
weeks). A direct relationship exists between the severity of acute 
side effects and the severity of late toxicities for some normal tis-
sues (19). Therefore establishing the MTD by monitoring acute 
effects is an imperfect but efficient surrogate for assessing late 
effects. A limitation to this approach is the potential to miss some 
late side effects that are clinically relevant (eg, radiation pneu-
monitis—3–6  months after radiation therapy; fibrosis, radiation 
proctitis, tracheoesophageal fistula, or memory deficits —months 
to years after radiation therapy). Although we are not minimizing 
these effects and realize their potential morbidity, such potential 
problems will be identified in subsequent lines of investigation, and 
therefore short-term toxicity assessment should be the major focus 
of early clinical testing. However, patients should understand the 
risks of potential late effects during the informed consent process 
and should be monitored for a sufficient period of time for the 
development of late effects. Although late effects will not be the 
primary endpoints of the phase I and II clinical trials, it is important 
to determine if a new radiation sensitizer has late-term toxicities so 
that this information is expeditiously captured through the trials 
and can be considered by the US Food and Drug Administration 
(FDA) and investigators for later phase trials.
Novel Clinical Trial Designs
The resources needed to design, open, conduct, and complete a 
clinical trial are substantial. Initiating and opening a series of inde-
pendent phase I studies with similar design and endpoints would 
be a poor use of scarce resources. A more efficient way to rapidly 
test novel agents in combination with radiation is through modular 
clinical trial platforms. In this regard, several agents can be rapidly 
tested in parallel noncomparative arms. This allows investigators 
to generate more clinical data within the same trial infrastruc-
ture with consistent eligibility, assessments, endpoints, method-
ology, and biomarker analyses. By establishing consistent clinical 
endpoints (eg, landmark survival), agents can be identified with a 
higher likelihood of success for validation testing in subsequent 
randomized controlled trials. Several platform-based clinical tri-
als [eg, I-SPY1 trial testing neoadjuvant drug therapy for patho-
logic response measurements in early-stage breast cancer prior to 
lumpectomy (20) and various BATTLE platforms for lung cancer 
trials at MD Anderson Cancer Center (21)] have confirmed the 
feasibility of such an approach. These have substantial benefits 
compared with traditional approaches because there is uniformity 
in eligibility and data collection, efficient enrollment of patients 
into various subgroup trials under the same enrollment/screening 
process, and elimination of protocol-dictated downtime that occurs 
when cohorts are filled by conducting multiple trials in tandem. 
They also decrease the administrative burden and costs of repeti-
tive institutional review board and other regulatory review through 
a master protocol.
Source of Agents and Path to Registration
Development of novel therapeutics as radiation enhancers requires 
the involvement of multiple partners. Traditionally, many of these 
agents have come from the pharmaceutical industry. However, 
combining drugs with radiation has not been a priority for industry 
partners because this is not a common pathway leading to FDA 
approval. This is particularly unfortunate because drug combina-
tions with radiotherapy are frequently employed in potentially 
curative therapies. It is therefore important for the FDA to recog-
nize that radiotherapy in combination with a novel drug could be a 
valid pathway for initial registration and establish clear guidance in 
this regard. Similarly, the pharmaceutical industry must recognize 
that combination trials with radiation may represent an opportunity 
for a first or new indication based upon improvement in cure rates 
in common solid tumors. The lack of efficacy when a new agent is 
combined with standard chemotherapy for metastatic disease does 
not necessarily imply that a clinical benefit might not be gleaned in 
the locally advanced setting when the novel agent is combined with 
radiation. The National Cancer Institute (NCI) Clinical Therapy 
Evaluation Program (CTEP) can serve as a critical intermediary 
in this regard. Specifically, CTEP should consistently issue mass 
solicitations for drug combination trials that have specific calls 
for proposals in combination with radiation and should simulta-
neously facilitate development of compounds as radiosensitizers 
within their portfolio, particularly through multiarm clinical trial 
platforms with multiple industry partners.
Funding Sources
The development of novel radiosensitizers should be financially 
supported consistent with other priorities in cancer research. 
The funding of preclinical studies can occur through established 
mechanisms including, but not limited to, seed funding by insti-
tutional/departmental assets and competitive grants through pri-
vate or public resources. For some academic centers, U01 and 
N01 mechanisms provide contractual agreements with CTEP 
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to conduct phase I  or phase II studies, respectively. The NCI-
sponsored cooperative groups represent an ideal forum to con-
duct clinical trials necessary to prove activity and efficacy, but 
not necessarily preclinical or early-phase studies. Given limited 
resources, studies must be scrutinized for scientific rationale 
and prioritized based on the scientific quality and clinical need. 
However, even with clinical study funding sources identified, 
often biomarker analyses and development cannot be completely 
supported through these means. By linking correlative biomarker 
studies with existing grant mechanisms (R01, P01, SPORE), 
applying for new competitive grants (CPRIT, R01), or establish-
ing scientific collaborations with groups and centers that have the 
expertise and funding but lack the clinical samples could all be 
alternative avenues to fund the critical biomarker analyses. Given 
the financial restrictions in clinical investigation, the economic 
benefits and thus prioritization of platform-based clinical trial 
designs should be recognized.
Programmatic examples of the 
opportunities and Challenges
In 2009, leadership at the Molecular Radiation Therapeutics Branch 
(MRTB) of the NCI identified a need to bring together key stake-
holders and experts in an attempt to develop an organized effort 
to develop novel radiosensitizers. These working groups were 
comprised of radiation biologists, translational scientists, and clini-
cians and focused on specific clinical areas of need (Supplementary 
Table 1, available online). Through government, private, and aca-
demic collaboration, these working groups have tackled many of 
the challenges and have operationalized many of the opportunities 
outlined in the sections above. We have briefly outlined the efforts 
of the Breast-to-Brain Metastases working group as an example of 
ongoing efforts of all working groups.
The Breast-to-Brain Metastases working group was the inaugu-
ral group established by the MRTB. The goal of this group, similar 
to the other groups, is to identify gaps in the preclinical research 
that would help advance some of the research in bringing targeted 
agents in combination with whole brain radiotherapy (WBRT) for 
brain metastases from breast cancer. Brain metastases involve more 
than 60 000 patients per year, the bulk of whom require WBRT 
as the standard of care. Breast and non–small cell lung cancers 
make up the majority of these patients. As systemic disease con-
trol improves, control of central nervous system disease becomes 
ever more important. Intracranial disease control is achieved in 
less than half of patients treated with WBRT alone, and escala-
tion of WBRT in brain metastases is untenable. Although there 
are numerous potential agents to combine with WBRT, PARP 
inhibitors comprise the class receiving the highest attention from 
the group. Ample preclinical data demonstrate the radiosensitizing 
effect of PARP inhibitors (22,23). An important early-phase study 
with ABT-888 (veliparib) combined with WBRT (NCT00649207) 
is ongoing. Another important key study involves adding a gamma-
secretase inhibitor RO4929097 to WBRT for breast cancer patients 
(NCT01217411).
Although most other agents with activity in breast and lung 
cancers (eg, VEGF inhibitors, EGFR inhibitors) have been shown 
in preclinical data to have radiosensitizing effects, they lack phase 
I safety data with WBRT. To rapidly develop novel radiosensitizers 
in combination with WBRT, the working group has focused atten-
tion on the new collaborative trial between the Radiation Therapy 
Oncology Group (RTOG) and the Korean Radiation Oncology 
Group. RTOG 1118 has been designed as a multiarm phase I/II 
randomized trial that incorporates multiple agents in comparison 
with WBRT alone. The phase I portion includes broad enrollment 
eligibility and focuses on safety. The phase II portion of the study 
limits eligibility to only breast and non–small cell lung cancers 
patients, with these studies being done in tandem as individual 
phase I  components get completed (with WBRT alone serving 
as control). Patients are randomized to the various agent experi-
mental arms with stratification for the primary tumor site (lung vs 
breast). The primary endpoint is intracranial response rate (RR) at 
4 months after WBRT. Early stopping rules are incorporated so 
that if the novel sensitizer does not improve RR by 5% or better, 
that arm of the trial will be dropped. A 15% improvement in RR 
makes the drug a potential agent to explore further in definitive 
randomized controlled trials. The trial will open first with three 
arms: 1) WBRT alone, 2) WBRT with cilengitide, and 3) WBRT 
with veliparib. A unique challenge facing development in this clin-
ical arena involves the need to maintain systemic disease control in 
a heavily pretreated patient population while focusing therapeutic 
attention on the central nervous system disease.
Summary and near-term milestones
In summary, we believe molecularly targeted approaches will best 
complement the technological advances that are already in place 
to help accelerate the pace of progress in radiation oncology. With 
the opportunities and challenges reviewed and recommendations 
presented, we are poised to meet these challenges to reach our ulti-
mate goal: improve cancer cure rates for our patients. Advances 
in cancer treatment, including radiotherapy, should optimally 
start with proper patient selection through innovative preclinical 
research (Figure  2). Continued progress in biomarker research 
using various in vitro and in vivo cancer models integrated with 
various genomic-scale datasets will hopefully accelerate the devel-
opment of new predictive biomarkers for patient selection and 
increase the number of agents with clearly validated biomarkers 
for upfront patient selection in clinical trials. Despite the clinical 
importance and multitude of potential agents, there are few incen-
tives for industry to develop or test novel radiosensitizers. A sys-
tematic and rational approach to the development and testing of 
novel radiosensitizers is needed, an operational process that the 
NCI MRTB working groups are beginning to tackle. Through a 
cooperative group/CTEP/industry partnership, a critical program-
matic national approach can be implemented to rapidly identify 
and test compounds. In the near term, we aim to identify agents 
with established biomarkers for each working group to move for-
ward through CTEP and industry as solicited or unsolicited con-
cept submissions. There are already several important studies or 
trial platforms being developed at each of the disease working 
groups that we hope to see activated within the next year. Finally, 
we encourage adoption of these workshop recommendations so as 
to accelerate the development of novel molecularly targeted thera-
pies in combination with radiation therapies.
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